Pharmacokinetics, absorption, distribution, metabolism and excretion of the MEK inhibitor zapnometinib in rats
Zapnometinib is a MEK inhibitor currently under clinical development for the treatment of COVID-19 and influenza. Zapnometinib has both antiviral and immunomodulatory effects. Information concerning the absorption, distribution, metabolism, and excretion of the compound following single oral doses o...
Main Authors: | Yvonne Füll, Christian Wallasch, Ashley Hilton, Oliver Planz |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-12-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1050193/full |
Similar Items
-
The MEK1/2 Inhibitor ATR-002 (Zapnometinib) Synergistically Potentiates the Antiviral Effect of Direct-Acting Anti-SARS-CoV-2 Drugs
by: André Schreiber, et al.
Published: (2022-08-01) -
Pharmacokinetics and Pharmacodynamics: A Comprehensive Analysis of the Absorption, Distribution, Metabolism, and Excretion of Psychiatric Drugs
by: Zainab Zakaraya, et al.
Published: (2024-02-01) -
BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis
by: Mattia Garutti, et al.
Published: (2022-12-01) -
The in vivo process of realgar from absorption to excretion
by: Yan Luo, et al.
Published: (2023-03-01) -
Lycopene: A Critical Review of Digestion, Absorption, Metabolism, and Excretion
by: Joseph Arballo, et al.
Published: (2021-02-01)